

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Sep 2026

efficacy of intravenous vitamin C combined with intravenous tranexamic acid in improving outcomes of intracerebral/intraventricular hemorrhages in non-traumatic ICH patients

Protocol summary

Study aim

-Evaluation of the combined therapeutic effect of intravenous tranexamic acid and intravenous Vitamin C in preventing the progression of intracerebral hemorrhage, improving three-month functional impairment (based on changes in the mRS score) and reducing mortality in patients with non-traumatic ICH patients.

Design

The clinical trial is a parallel-group, double-blind, randomized, phase 3 study with a control group, involving 60 patients. Permuted Block Randomization will be used to allocate patients into the two control and intervention groups.

Settings and conduct

Study Design: Double-blind trial at Imam Reza Hospital, Tabriz, monitoring patients for 90 days post-intervention. Blinding: Both participants and the executive study team will be blinded to group assignments (intervention vs. control). Follow-up: Assessments conducted at 24 hours, 3, 7, 30, and 90 days post-admission.

Participants/Inclusion and exclusion criteria

Inclusion Criteria: Adults (>18 yrs) with acute, non-traumatic intracerebral hemorrhage, presenting within 6 hours of symptom onset. Exclusion Criteria: Patients with hemorrhage due to anticoagulants, thrombolysis, or underlying structural issues (e.g., AVM, aneurysm, tumor).

Intervention groups

Intervention Group: Receives a loading dose of IV tranexamic acid (1g in 100ml NS), followed by 1g IV infusion over 8 hours (total 2g/24h), plus 4g IV vitamin C daily for 4 days. Control Group: Receives only IV tranexamic acid as part of standard ICH care. Treatment Duration: Tranexamic acid for 24 hours, vitamin C for 4 days in the intervention group.

Main outcome variables

Prevention of intracerebral hemorrhage progression, improvement in three-month functional outcomes (based on changes in the modified Rankin Scale - mRS), and reduction in mortality rate in patients with non-traumatic intracerebral hemorrhage

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20170609034406N15**

Registration date: **2026-03-31, 1405/01/11**

Registration timing: **prospective**

Last update: **2026-03-31, 1405/01/11**

Update count: **0**

Registration date

2026-03-31, 1405/01/11

Registrant information

Name

Afshin Gharekhani

Name of organization / entity

Faculty of Pharmacy/Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 3334 1315

Email address

gharekhanian@tbzmed.ac.ir

Recruitment status

recruiting

Funding source

Expected recruitment start date

2026-06-22, 1405/04/01

Expected recruitment end date

2026-09-23, 1405/07/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

efficacy of intravenous vitamin C combined with intravenous tranexamic acid in improving outcomes of intracerebral/intraventricular hemorrhages in non-traumatic ICH patients

Public title

Evaluation of the combined therapeutic effects of intravenous Vitamin C and intravenous tranexamic acid on improving outcomes in patients with non-traumatic ICH

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Individuals over 18 years of age with acute, non-traumatic intracerebral hemorrhage, within a maximum of 6 hours from the onset of bleeding

Exclusion criteria:

Patients with intracerebral hemorrhage secondary to anticoagulant use, thrombolysis, or known structural abnormalities such as arteriovenous malformations (AVMs), aneurysms, or tumors Patients with contraindications to tranexamic acid (such as active intravascular clotting, a history of thromboembolic diseases, or hypersensitivity to tranexamic acid) Modified Rankin Scale (mRS) >4 Glasgow coma scale <5 Intracerebral hemorrhage secondary to trauma Subarachnoid hemorrhage (SAH) Subdural hemorrhage (SDH) Epidural hemorrhage (EDH) Pregnant or lactating women at the time of randomization Geographical or other factors that hinder follow-up at 90 days, such as lack of a permanent address or contact phone number

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **60**

More than 1 sample in each individual

Number of samples in each individual: **30**

A total of 60 patients (30 patients in each group) with acute non-traumatic intracerebral hemorrhage, meeting the predefined inclusion and exclusion criteria, will be enrolled and allocated into the intervention and control groups. Patients in the intervention group will receive 1 g of intravenous tranexamic acid diluted in 100 mL of normal saline as a loading dose, followed by an additional 1 g administered as an intravenous infusion

over eight hours (a total of 2 g of intravenous tranexamic acid within 24 hours), along with 4 g of intravenous vitamin C daily for four consecutive days. The control group will receive only intravenous tranexamic acid in addition to all other standard treatments and routine care related to ICH.

Randomization (investigator's opinion)

Randomized

Randomization description

In this study, Permuted Block Randomization is used to allocate patients into two groups: the control and the intervention groups. A total of 25 blocks of 4 participants are planned. In this method, each block contains an equal number of patients in the intervention and control groups. Random numbers in this study are generated using Microsoft Excel to create the random block assignments as well as the random allocation of patients to the groups.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this phase 3 clinical trial, a double-blind design will be implemented to ensure the validity of the results and to minimize any potential sources of bias. This approach guarantees that neither the participants (patients) nor the study personnel (including physicians, nurses, data collectors, and outcome assessors) are aware of the treatment allocation for each patient within the intervention or control groups. According to the study protocol, the control group will receive intravenous tranexamic acid, while the intervention group will receive intravenous tranexamic acid in combination with intravenous vitamin C. To maintain blinding, both injectable agents (tranexamic acid and vitamin C) will be prepared and packaged in a manner that ensures complete similarity in appearance, color, volume, odor, and other physical characteristics. All injectable solutions will be labeled with unique identification codes, and the code-allocation key (indicating which code corresponds to which treatment combination) will be securely kept by an independent individual or entity with no involvement in patient care, trial execution, or data collection and analysis. This strategy ensures that information regarding the administration of active vitamin C remains concealed until the completion of data collection and analysis, thereby preventing any potential influence on clinical judgment or outcome assessment.

Placebo

Not used

Assignment

Parallel

Other design features

Double-blind, Randomized, Block-randomized Clinical Trial. Intervention Group: Intravenous TXA + Intravenous Vitamin C. Control Group: Intravenous TXA, along with other standard treatments and care for ICH. Monitoring: At 24 hours, 3 days, 7 days, 30 days, and 90 days.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tabriz University of Medical Sciences

Street address

No 2 Central Building , Tabriz University of Medical Sciences , Golgasht Street , Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5165665931

Approval date

2026-03-17, 1404/12/26

Ethics committee reference number

IR.TBZMED.REC.1404.891

Health conditions studied

1

Description of health condition studied

Non-traumatic intracerebral and intraventricular hemorrhage

ICD-10 code

I61

ICD-10 code description

Nontraumatic intracerebral hemorrhage

Primary outcomes

1

Description

Functional outcome measured by the Modified Rankin Scale (mRS) score at day ninety after randomization

Timepoint

Baseline before randomization and day ninety (or discharge day) after randomization

Method of measurement

Use of the modified Rankin Scale questionnaire (range 0 to 6) administered in person by a trained assessor who is blinded to group allocation

Secondary outcomes

1

Description

Hematoma expansion defined as an increase in intracerebral hemorrhage volume of at least thirty three percent or at least six milliliters between baseline and follow up imaging.

Timepoint

Baseline imaging at enrollment and follow up imaging at twenty four to seventy two hours after randomization

Method of measurement

Non contrast computed tomography scans with hematoma volume measured by the ABC divided by two method or by planimetry on the hospital imaging workstation read by a radiologist who is blinded to group allocation

2

Description

All-cause mortality up to the day of discharge (or death) following randomization

Timepoint

From the time of randomization until the day of discharge (or death)

Method of measurement

Review of the hospital record and follow-up telephone assessment by the blinded assessor, confirmed by official records where permitted

Intervention groups

1

Description

Intervention group: Patients in the intervention group will receive 1 gram of intravenous tranexamic acid diluted in 100 milliliters of normal saline as a loading dose, followed by an intravenous infusion of 1 gram over eight hours (a total of 2 grams of intravenous tranexamic acid within 24 hours), along with 4 grams of intravenous vitamin C daily for four days.

Category

Treatment - Drugs

2

Description

Control group: They will receive only intravenous tranexamic acid in addition to other standard treatments and care for ICH.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Emam Reza Hospital

Full name of responsible person

Afshin Gharekhani

Street address

Golgasht street

City

Tabriz

Province

East Azarbaijan

Postal code

5147663419

Phone

+98 41 3337 2250

Email

gharekhanian@tbzmed.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Afshin Qarekhani

Street address

Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3337 2250

Email

gharekhanian@tbzmed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Afshin Gharekhani

Position

Associate Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Golgasht Ave., Faculty of Pharmacy/Tabriz University of Medical Sciences/Daneshgah Street/Tabriz/Iran.
P.O.Box 5166

City

Tabriz

Province

East Azarbaijan

Postal code

5147663419

Phone

+98 41 3334 1315

Fax

+98 41 3334 4798

Email

gharekhanian@tbzmed.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Afshin Qarekhani

Position

Associate Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Golgasht Ave., Faculty of Pharmacy/Tabriz University of Medical Sciences/Daneshgah Street/Tabriz/Iran.
P.O.Box 5166

City

Tabriz

Province

East Azarbaijan

Postal code

5147663419

Phone

+98 41 3334 1315

Fax

+98 41 3334 4798

Email

gharekhanian@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Afshin Qarekhani

Position

Associate Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Golgasht Ave., Faculty of Pharmacy/Tabriz University of Medical Sciences/Daneshgah Street/Tabriz/Iran.
P.O.Box 5166

City

Tabriz

Province

East Azarbaijan

Postal code

5147663419

Phone

+98 41 3334 1315

Fax

+98 41 3334 4798

Email

gharekhanian@tbzmed.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Deidentified IPD (baseline and follow-up clinical variables, outcomes, adverse events), study protocol, statistical analysis plan, blank informed consent form, analytic code, and data dictionary.

When the data will become available and for how long

Available upon publication of the primary results and for three years thereafter.

To whom data/document is available

Qualified researchers from academic or non-profit institutions with a sound research proposal.

Under which criteria data/document could be used

Non-commercial use for scientifically and ethically appropriate projects; approval by an institutional review board or ethics committee when applicable; execution of a data use agreement that protects participant privacy.

From where data/document is obtainable

Contact the Principal Investigator via email (forouzan.abbasgholizadeh1998@gmail.com).

Documents may also be posted on the Tabriz University of Medical Sciences repository if available.

What processes are involved for a request to access data/document

Submit a brief proposal and analysis plan to the Principal Investigator. Requests are reviewed by the study steering team within 30 days. If approved, a data use agreement will be executed and the deidentified dataset, code, and data dictionary will be shared via a secure link.

Comments